|Bid||11.76 x 1500|
|Ask||12.28 x 400|
|Day's Range||11.50 - 12.33|
|52 Week Range||5.50 - 18.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.38|
After the expensive Ionic smartwatch fell short of expectations, the company is betting on an inexpensive smartwatch for the masses.
Heavy short interest in Fossil stock laid the foundation for explosive gains when the company delivered a fourth-quarter earnings beat.
Fossil (FOSL) continues to gain from higher wearables demand. However, the company struggles against weakness in business segments.
NEW YORK, March 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Fitbit (FIT) needs to improve its profit margins and drive operational efficiency to offset declining device sales. Fitbit reduced its inventory by 46% YoY (year-over-year) in 4Q17 to $123.9 million, compared with $230.4 million in 4Q16. As shown in the above table, Fitbit has considerably reduced inventory in each of the last four quarters.
Fossil Group Inc (NASDAQ:FOSL) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
What time is it? Time to push back on proposed tariffs on imported metal that President Donald Trump announced this week.
FIS Astec Analytics has released its weekly list of the most popular stocks among short sellers. This week’s list is topped by a dating website company making its first appearance on the list. Here’s a ...
Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included a top retailer, a leading pharmaceutical company and a regional bank. Bearish calls featured an industrial ...
IN THE NEWS Fossil Group Inc (NASDAQ: FOSL ) shares soared higher by more than 60 percent Wednesday after the company shocked Wall Street and short sellers with better-than-feared fourth-quarter earnings ...
- Fennec Pharma's (FENC) lead drug sodium thiosulfate headed for U.S. FDA review in coming months and will likely be approved imminently based on strong Phase 3 trial results. Could generate $100-$200 ...